Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of hydroxychloroquine in medicine for preventing and treating systemic lupus erythematosus

A systemic technology for lupus erythematosus, applied in the biological field, can solve the problems of pathogenic mechanism and effective intervention treatment plan, which have not been reported in literature.

Pending Publication Date: 2022-02-01
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its specific pathogenic mechanism and effective intervention therapy have not been reported in the literature.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hydroxychloroquine in medicine for preventing and treating systemic lupus erythematosus
  • Application of hydroxychloroquine in medicine for preventing and treating systemic lupus erythematosus
  • Application of hydroxychloroquine in medicine for preventing and treating systemic lupus erythematosus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Comparison of lupus phenotypes between wild-type mice and NCF1 p.R90H gene mutant mice

[0034]Intervention method: Select 10-12 weeks old wild-type mice (WT) and NCF1 p.R90H gene mutant mice (KI), apply 5% imiquimod (IMQ) (2mg / mouse / times), once every other day, for 6-12 weeks, to induce the lupus model. At the same time, for WT and KI mice in the treatment group, hydroxychloroquine (10 mg / kg / day) was administered orally, and the therapeutic effect was detected. The phenotypes of wild-type mice and NCF1 knock-in mice were tested after applying imiquimod cream for 9 weeks.

[0035] Four groups of wild type mice (WT), NCF1 p.R90H gene mutant mice (KI), wild type lupus mice (WT+Lupus), NCF1 p.R90H gene mutant lupus mice (KI+Lupus) Experimental results such as figure 1 , 2 , 3 and 4, where figure 1 For survival statistics, figure 2 For spleen pictures and weight comparisons, image 3 Hematoxylin-eosin staining (H&E) pictures of mouse kidneys, glomerulus ...

Embodiment 2

[0041] Example 2 The application of hydroxychloroquine can significantly reduce the lupus symptoms of NCF1 p.R90H gene mutant mice

[0042] Use HCQ to treat wild-type lupus mice (WT Lupus+HCQ) and NCF1 p.R90H gene mutant lupus, and obtain corresponding mouse wild-type lupus mice treatment group (WT Lupus+HCQ), NCF1 p.R90H gene mutation Type lupus mouse treatment group. And wild-type lupus mice (WT+Lupus), NCF1 p.R90H gene mutant lupus mice (KI+Lupus), wild-type lupus mice treatment group (WT Lupus+HCQ), NCF1 p.R90H gene mutant The phenotypes of the lupus mouse treatment group (KI Lupus+HCQ) were detected and compared. Test results such as Figure 5 , 6 , 7 and 8. The wild-type mice and the NCF1 knock-in mice were given imiquimod cream for 7 weeks at the same time.

[0043] like Figure 5 As shown, wild-type lupus mice (WT+Lupus), NCF1 p.R90H gene mutant lupus mice (KI+Lupus), wild-type lupus mice treatment group (WT Lupus+HCQ), NCF1 p.R90H gene mutation Survival statist...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for preventing and treating NCF1p.R90H gene mutation type systemic lupus erythematosus and application of hydroxychloroquine in the medicine for preventing and treating the NCF1p.R90H gene mutation type systemic lupus erythematosus, and relates to the technical field of biology. The medicine for preventing and treating the NCF1p.R90H gene mutation type systemic lupus erythematosus comprises hydroxychloroquine. The invention relates to application of hydroxychloroquine in preparation of the medicine for preventing and treating NCF1p.R90H gene mutant systemic lupus erythematosus. The invention provides a new application of hydroxychloroquine in NCF1p.R90H gene mutant systemic lupus erythematosus, and experimental comparison shows that the phenotype of lupus of an NCF1p.R90H gene mutant mouse is heavier; and the application of the hydroxychloroquine can obviously relieve lupus symptoms of NCF1p.R90H gene mutant mice. The invention develops a precise targeted therapeutic drug for treating lupus based on genetic factors.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to an application of hydroxychloroquine in preventing and treating systemic lupus erythematosus. Background technique [0002] Hydroxychloroquine (Hydroxychloroquine, HCQ) 4-aminoquinoline derivative antimalarials are widely used clinically because of their immunosuppressive and antiviral effects. The immunosuppressive effects of hydroxychloroquine mainly include: inhibiting lysosomal activity and autophagy; inhibiting the production of pro-inflammatory cytokines; inhibiting immune response signaling pathways. Hydroxychloroquine can stabilize lysosomal membranes and reduce the release of lysosomal enzymes; at the same time, it acts as a prostaglandin antagonist, reducing the production of prostaglandins and leukotrienes, thereby exerting anti-inflammatory effects. [0003] Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple systems and organs, characterized b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4706A61P37/02
CPCA61K31/4706A61P37/02
Inventor 沈南周海波孟尧
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com